Non-Alcoholic Fatty Liver Disease Market Projected for Strong Expansion by 2032, per DelveInsight | Major Industry Players: Pfizer, Eli Lilly and Company, CohBar, Inc., Hoffmann-La Roche, Amgen, Merck Sharp & Dohme LLC, Abbott
DelveInsight’s comprehensive new report, “Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032,” presents an in-depth evaluation of Non-Alcoholic Fatty Liver Disease across the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The analysis includes historical and forecasted epidemiological data, market trends, and an extensive therapeutic pipeline assessment.
Learn More About Market Landscape, Drug Uptake, and Epidemiology Trends:
Key Insights from the Non-Alcoholic Fatty Liver Disease Market Forecast
The Non-Alcoholic Fatty Liver Disease market is set for substantial growth, with a strong Compound Annual Growth Rate (CAGR) projected through the 2019–2032 forecast period.
Recent Clinical Developments:
December 2024: Galectin Therapeutics released results from the NAVIGATE global trial evaluating belapectin in individuals suffering from Metabolic Dysfunction-Associated Steatohepatitis cirrhosis with portal hypertension.
October 2024: PharmaIN Corporation reported interim Phase I data for PHIN-214, a leading investigational drug for preventing and treating decompensated cirrhosis.
Therapeutic Pipeline Overview for Non-Alcoholic Steatohepatitis
The therapeutic landscape includes multiple innovative drug classes in development:
Farnesoid X receptor (FXR) agonists
Fibroblast growth factor 21 (FGF21) and fibroblast growth factor 19 (FGF19) analogs
Glucagon-like peptide-1 (GLP-1) receptor agonists
Peroxisome proliferator-activated receptor (PPAR) modulators
Thyroid hormone receptor beta (THR-β) agonists
Epidemiological Context and Disease Overview
According to the American Liver Foundation, Non-Alcoholic Fatty Liver Disease is the most widespread chronic liver disease in the United States, impacting nearly 25% of the adult population, with around 20% of those progressing to Non-Alcoholic Steatohepatitis.
The Bagnacavallo Study (Foschi et al., 2019) conducted in Northern Italy revealed a prevalence of 46% in patients with abnormal liver enzyme levels, compared to 22% in individuals with normal enzyme profiles.
Leading Companies in the Non-Alcoholic Fatty Liver Disease Space
Notable pharmaceutical developers include:
Inventiva Pharma
Eli Lilly and Company
Madrigal Pharmaceuticals
Intercept Pharmaceuticals
89bio
Novo Nordisk A/S
NeuroBo Pharmaceuticals
J2H Biotech
Haisco Pharmaceutical
Altimmune
GlaxoSmithKline
Axcella Health
AstraZeneca
Gannex Pharma
Dexa Medica
Boehringer Ingelheim
Can-Fite BioPharma
Rivus Pharmaceuticals
Regeneron Pharmaceuticals
MediciNova
Highlighted Non-Alcoholic Fatty Liver Disease Drug Candidates in Development
Lanifibranor – Inventiva Pharma
Tirzepatide – Eli Lilly and Company
MGL-3196 (Resmetirom) – Madrigal Pharmaceuticals
Obeticholic acid – Intercept Pharmaceuticals
Pegozafermin – 89bio
Semaglutide – Novo Nordisk A/S
DA-1241 – NeuroBo Pharmaceuticals
NNC0194 0499 – Novo Nordisk A/S
J2H-1702 – J2H Biotech
HSK31679 – Haisco Pharmaceutical
Pemvidutide – Altimmune
GSK4532990 – GlaxoSmithKline
AXA1125 – Axcella Health
AZD9550 – AstraZeneca
ASC41 2mg – Gannex Pharma
Proliverenol – Dexa Medica
Survodutide – Boehringer Ingelheim
Namodenoson – Can-Fite BioPharma
HU6 – Rivus Pharmaceuticals
ALN-HSD – Regeneron Pharmaceuticals
MN-001 – MediciNova
These emerging treatments are expected to transform the disease landscape over the next decade as they progress through various development stages.
Understanding Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease is a spectrum of liver conditions characterized by excessive fat accumulation in liver cells, not caused by alcohol intake. It ranges from simple steatosis to more advanced conditions like Non-Alcoholic Steatohepatitis, fibrosis, cirrhosis, and ultimately hepatocellular carcinoma.
Epidemiological Trends from 2019 to 2032
The report outlines:
Overall prevalence rates of Non-Alcoholic Fatty Liver Disease
Breakdown by disease severity
Gender-specific prevalence statistics
Cases segmented into acute and chronic forms
It incorporates projections and analysis from seven key global markets and leverages insights from major clinical studies and expert reviews.
Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market : https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr
Drug Uptake and Pipeline Progress
This section evaluates how emerging therapies are being adopted, including:
Patient response rates
Forecasted sales and market share
Penetration rates in target populations
It also tracks the research and development pipeline, with updates on clinical trials, licensing agreements, strategic collaborations, and drug advancement timelines.
Market Forces: Drivers and Opportunities
Market Strengths:
Ongoing clinical trials and a rich research environment for Non-Alcoholic Steatohepatitis are paving the way for new therapies.
Market Opportunities:
The United States offers one of the largest growth opportunities due to a high patient population with unmet therapeutic needs.
Report Scope
Study Period: 2019–2032
Geographies Covered: United States, EU5 (Germany, France, Italy, Spain, United Kingdom), Japan
Company and Drug Coverage: Comprehensive list of leading pharmaceutical companies and therapeutic candidates
Strategic Tools Used: SWOT Analysis, PESTLE, Porter’s Five Forces, BCG Matrix
Additional Insights: Market access conditions, pricing, reimbursement, and expert perspectives
To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit
Table of Contents (Key Sections):
Introduction
Executive Summary
SWOT Analysis
Patient Share Overview
Market Overview
Disease Background
Epidemiology Analysis
Country-specific Patient Insights
Treatment Landscape
Unmet Needs
Emerging Therapies
Market Forecast and Outlook
Regional Market Analysis (2019–2032)
Market Access & Reimbursement
Market Drivers
Market Barriers
Appendix
Methodology
About DelveInsight
Disclaimer
Related Reports:
Non-Alcoholic Fatty Liver Disease Pipeline https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr
"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Alcoholic Fatty Liver Disease market. A detailed picture of the Non-Alcoholic Fatty Liver Disease pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Fatty Liver Disease treatment guidelines.
Non-Alcoholic Fatty Liver Disease Epidemiology https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-epidemiology-forecast?utm_source=reportstore&utm_medium=promotion&utm_campaign=akpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Alcoholic Fatty Liver Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight:
Adult T-Cell Leukemia Market | Arthralgia Market | Atrial Flutter Market | Attention Deficit Hyperactivity Disorder Market | Bacterial Meningitis Market | Biopsy Devices Market | CART Pipeline | Chlamydia Infections Market | Chronic Neuropathic Pain Market | Convulsive Seizures Market | Coronary Angioplasty Market | Diabetic Gastroparesis Market | Diabetic Nephropathy Market | Electrophysiology Devices Market | Ewing Sarcoma Market | Fabry Disease Market | Gene Therapy In CNS Disorder Market | Glioblastoma Multiforme Market | Graves Disease Market | Hay Fever Conjunctivitis Market | Heart Pump Devices Market | Hydrocephalus Treatment Market | Impetigo Market | Indwelling Catheters Market | Intracranial Hemorrhage Market | Lambert-Eaton Myasthenic Syndrome Market | Lumbar Degenerative Disc Disease Market | Meibomian Gland Dysfunction Market | Metastatic Merkel Cell Carcinoma Market | Metastatic Prostate Cancer Market | Molluscum Contagiosum Market | Myopia Progression Market | NMOSD Market | Nocturia Market | Nonalcoholic Steatohepatitis Market | Nontuberculous Mycobacterial Infections Market
Other Reports by DelveInsight:
https://www.delveinsight.com/sample-request/late-stage-chronic-kidney-disease-ckd-pipeline-insight
https://www.delveinsight.com/sample-request/leiomyosarcoma-epidemiology-forecast
https://www.delveinsight.com/sample-request/leishmaniasis-pipeline-insight
https://www.delveinsight.com/sample-request/leukapheresis-market
https://www.delveinsight.com/sample-request/leukotriene-antagonist-pipeline-insight
https://www.delveinsight.com/sample-request/lice-infestations-market
https://www.delveinsight.com/sample-request/lipodystrophy-syndrome-ls-market-2027
https://www.delveinsight.com/sample-request/liq-861-drug-insight-and-market-forecast
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Comments
Post a Comment